EBS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Emergent BioSolutions Inc (EBS) is not a good buy for a beginner, long-term investor at this time. The stock is showing weak technical indicators, negative financial performance, insider selling, and a lack of positive catalysts. Additionally, analysts have lowered their price targets, and options data suggests bearish sentiment. Given the user's investment profile and the lack of strong signals, holding off on this investment is recommended.
The MACD histogram is negative (-0.13) and contracting, indicating weak momentum. RSI is at 22.127, suggesting oversold conditions but no clear signal. Moving averages are converging, and the stock is trading below key pivot levels (Pivot: 8.614, Current Price: 8.10). Support levels are at S1: 7.941 and S2: 7.526, indicating limited upside potential.
NULL identified. No recent news or significant positive developments.
Analysts have lowered the price target from $15 to $12 due to earnings misses and reduced expectations.
Insiders have increased selling activity by 207.62% over the last month.
Financial performance shows declining revenue (-23.63% YoY) and negative net income (-$54.6M).
Stock trend analysis predicts further declines (-3.37% in the next week, -13.74% in the next month).
In Q4 2025, revenue dropped by 23.63% YoY to $148.7M. Net income improved but remains negative at -$54.6M, up 74.44% YoY. EPS increased to -1.04, up 79.31% YoY. Gross margin improved to 42.91%, up 8.94% YoY. Overall, the company is struggling with declining revenue and profitability.
H.C. Wainwright lowered the price target from $15 to $12 while maintaining a Buy rating. The downgrade reflects reduced earnings expectations following an earnings miss.
